Enteroviruses (EV) are common causes of infection with diverse clinical presentation. The clinical outcome ranges from mild febrile illness to severe fatal events oftentimes arising from rapidly progressive cardiopulmonary failure. Most EV infections are asymptomatic or cause a mild febrile illness; however, aseptic meningitis, encephalitis, acute flaccid paralysis, myopericarditis, hand, foot and mouth disease (HFMD), and neonatal sepsis-like disease are well recognized syndromes. The genus EV is a member of the Picornaviridae family. There are over 100 serotypes infecting humans that are classified into 4 EV species (A, B, C, and D). The gene sequence of the viral capsid protein VP1 is used to identify enterovirus serotypes and genotypes using phylogenetic analysis. Equally important is the evaluation of gene sequence variation of a particular genotype over time to determine the evolution dynamics of the virus.
Nonpolio enteroviruses (npEVs) have been recognized to cause neurologic syndromes since their discovery and differentiation from polio in 1948 [1] . In recent years, there have been multiple outbreaks around the world associated with EV (A16, A71, D68, etc) [2] . These outbreaks have been notable because of their increased rates of neurologic manifestations, increased severity, and unusually high mortality rates [2] . These epidemics have prompted renewed investigation into npEV vaccine candidates, and research is ongoing in China, Taiwan, Singapore, and Australia [3] . However, the diversity and plasticity of EV, thought to be due to high mutation rates as well as genomic ribonucleic acid recombination, present a problem for maintaining an updated vaccine [4] .
Enterovirus A71 is a well recognized cause of severe HFMD in children. It was first isolated in California in 1969 from an infant with encephalitis [5] . Large outbreaks of EV-A71-related HFMD have been described from many countries in Asia and the Pacific Rim. These outbreaks are associated with substantial morbidity, neurologic sequelae, and mortality in children [6] . The severity of EV-A71 outbreaks vary and appears to be related to the circulating genotype [7] . Children infected with genotype B4 appear to have fewer central nervous system complications compared with those infected with other genotypes. Three EV-A71 vaccines have been approved for use in mainland China because of their demonstrated safety and efficacy [8] .
The article by Thao et al in the current issue of the Journal of Infectious Diseases presents a description of circulating EV-A71 genotypes and sub-genotypes within Vietnam as well as a proposed path of virus migration and genetic diversity in the region. The study characterized the epidemiology and long-term evolution of 4 EV-A71 genotypes: C1, C4, C5, and B5. This was done by testing samples collected from patients with symptoms and signs of HFMD from 2003 to 2013 in Vietnam. Sequencing of the VP1 gene was used to perform typing and phylogenetic analysis, and these sequences were compared with those from GenBank to generate migratory models for the genotypes. The authors found that specific genotypes would become endemic in a region (C4 in China, C5 in Vietnam, and B5 in Taiwan and Malaysia) and would then act as epidemic sources for other regions.
In this study, as well as others, the C4 genotype of EV-A71 has been associated with higher mortality rates in Asia [9] . In recent studies, it has become the focus of investigation, and vaccines based on C4 are currently the only EV-A71 vaccines available on a national market (specifically China) [3] . However, as Thao et al note, the C4 genotype is not the only genotype that causes mortality, and it is not the predominant genotype in many parts of the world. From the EV-71 vaccine phase 3 trials, we know that the current Chinese C4 vaccines have a high efficacy of preventing HFMD; however, at least 2 of the vaccines had decreased efficacy with other EV-71 syndromes [10] [11] [12] . This raises the question of whether the vaccines are too specific to make a lasting clinical impact. For example, cross-neutralization immunogenicity studies were performed for a candidate vaccine in Taiwan, and it was found that although it elicited a strong response against the C4a strain, it did not evoke a significant response for the C4b strain. Now, based on the Thao et al study, this may not be of clinical importance, because the C4a strain has largely replaced the C4b strain. However, Thao et al also noted that the C4 genotype had the highest nucleotide substitution rate of all of the genotypes, which may indicate the potential for further divergence.
In addition, EV-71 vaccines have not shown cross-protection for other enteroviral species [10] . This will have a significant impact on the utility of these vaccines worldwide. Even within a single country, multiple species contribute to the overall disease burden [13] . This overall burden translates not only into morbidity and mortality, but also economic cost. In 2011, the overall cost associated with HFMD in China was more than $7.66 million, and EV-A71 only accounted for ~46% of that cost [14] . These calculations do not include other enteroviral syndromes even though these patients frequently seek medical care [15] .
This raises the additional question as to what should be done to prevent other enterovirus species that have caused outbreaks and severe syndromes worldwide. For example, outbreaks have been attributed to EV-D68 in the United States and Europe, resulting in increased hospitalization due to severe lower respiratory disease and sporadic episodes of flaccid paralysis [16] . In addition, EV-A16 cocirculated with EV-A71 in the Chinese outbreak in 2009, although it played a subsidiary role [17] . For this reason, preclinical studies of bivalent vaccines (EV-A71 and EV-A16) have been initiated in Australia and China [3] . Bi-or multivalent vaccines could provide a solution for recent epidemics, either as part of a mass vaccination program or an epidemic response. As a case in point, trivalent poliovirus vaccines provided an effective solution to the polio epidemic and have enabled near eradication of the disease worldwide [18] .
However, with the high genetic mutation and recombination rates that characterize enteroviruses, one must ask whether vaccinations targeting specific species will truly provide a long-term solution. One issue in the past has been that the epidemic strains have evolved faster than vaccines could be created. One case of this in the history of EV vaccine development involved an EV-A71 vaccine created in the former Union of Soviet Socialist Republics (USSR) in response to a Bulgarian outbreak in 1975 [19] . In this instance, the vaccine was found to be safe and immunogenic, but efficacy could not be tested due to a lack of further outbreaks.
CONCLUSIONS
For the time being, species-specific vaccines (mono-or multivalent) seem like the most practical method of preventing severe neurologic syndromes due to enterovirus. Data such as those collected by Thao et al should contribute to the discussion of which genotypes and sub-genotypes are included as the enterovirus vaccine story continues to progress. Understanding viral migration and epidemic potentials through active surveillance networks will continue to inform these vaccine efforts. An active surveillance network can provide timely information on relevant molecular and antigenic changes useful for predicting clinical outcome and updating strain formulation in vaccines. This is similar to what is done for strain selection in vaccines against seasonal influenza, although these vaccines require continuous adjustments due to changes in the circulating strains. This has resulted in significant interest in a universal influenza vaccine that would provide protection despite antigenic shifts or drifts [20] . We would propose that a similar approach should be considered for enterovirus vaccines, which would allow the prevention of epidemics, rather than simply a reaction to them. 
